课件：---耐药背景下CAP的个体化治疗-CME_ ().ppt

Summary-CAP 呼吸FQs有效覆盖MDRSP、非典型病原体以及ESBL- 肠杆菌科细菌,在治疗CAP中占有重要地位。大剂量左氧和环丙作为抗铜绿假单胞菌联合治疗的重要选择之一。 ?-内酰胺＋新大环内酯 -肺炎链球菌对大环内酯耐药并不影响其作为联合治疗的选择 (PK/PD特性、细胞内浓度、抑制肺链溶血素、炎症和免疫调节作用;临床有效性) -如何选择?-内酰胺则要依赖对MDRSP以及MDR肠杆菌科危险因素评价 MDR革兰阴性杆菌感染危险因素:高龄、基础疾病、近期住院(ICU)、近期接受侵袭性 操作(气管插管/切开)、近期使用抗菌药物等 抗MRSA药物的使用:要充分评价是否有H-MRSA在社区发作可能性 No simplistic policy √ 耐药背景下的个体化治疗-让我们一起努力 Х Thank You 后面内容直接删除就行 资料可以编辑修改使用 资料可以编辑修改使用 资料仅供参考，实际情况实际分析 主要经营：课件设计，文档制作，网络软件设计、图文设计制作、发布广告等 秉着以优质的服务对待每一位客户，做到让客户满意！ 致力于数据挖掘，合同简历、论文写作、PPT设计、计划书、策划案、学习课件、各类模板等方方面面，打造全网一站式需求 * The introduction of every new class of antimicrobial agents is followed by emergence of resistance. By 1962, penicillin-resistant S. aureus were a major threat in hospitals and nurseries. By the 1970s, methicillin-resistant S. aureus had emerged and spread, a phenomenon that encouraged widespread use of vancomycin. In the 1990s, vancomycin-resistant enterococci emerged and rapidly spread; most of these organisms are resistant to other traditional first-line antimicrobial drugs. In 1997, the first S. aureus strains with reduced susceptibility to vancomycin were documented, prompting concerns that S. aureus fully resistant to vancomycin may be on the horizon. In June 2002, the first case of vancomycin-resistant S. aureus was detected; the patient was receiving chronic hemodialysis. 要点： 影响细菌学的修正因子（见幻灯）。 IDSA has updated its guidelines for empiric therapy of community-acquired pneumonia.1 An important consideration is appropriate use of antipseudomonal agents in this setting. For patients admitted to the hospital ICU with community-acquired pneumonia for whom pseudomonal infection is not an issue, ertapenem is a preferred treatment option.1 Patients who have community-acquired pneumonia and risk factors for pseudomonal infection—including severe structural lung disease such as bronchiectasis, or recent antibiotic therapy or recent prior hospitalization, especially in the ICU—require different therapy. For these patients,